Role of Conserved Tyrosine Lid Residues in the Activation of the M2 Muscarinic Acetylcholine Receptor
Molecular Pharmacology · 2023
DOI: 10.1124/molpharm.122.000661 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmacology, 2023. Verfasst von Vi Pham und 6 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Biology (V.P., G.T., A.C., D.M.T., C.V.), ARC Industrial Transformation Training Centre for Cryo-Electron Microscopy of Membrane Prote…. Hauptthemen laut MEDLINE: Muscarinic Agonists, Tyrosine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
The development of subtype selective small molecule drugs for the muscarinic acetylcholine receptor (mAChR) family has been challenging. The design of more selective ligands can be improved by understanding the structure and function of key amino acid residues that line ligand binding sites. Here we study the role of three conserved key tyrosine residues [Y1043.33, Y4036.51, and Y4267.39 (Ballesteros and Weinstein numbers in superscript)] at the human M2 mAChR, located at the interface between the orthosteric and allosteric binding sites of the receptor. We specifically focused on the role of the three tyrosine hydroxyl groups in the transition between the inactive and active conformations of the receptor by making phenylalanine point mutants. Single-point mutation at either of the three positions was sufficient to reduce the affinity of agonists by ∼100-fold for the M2 mAChR, whereas the affinity of antagonists remained largely unaffected. In contrast, neither of the mutations affected the efficacy of orthosteric agonists. When mutations were combined into double and triple M2 mAChR mutants, the affinity of antagonists was reduced by more than 100-fold compared with the wild-type M2 receptor. In contrast, the affinity of allosteric modulators, either negative or positive, was retained at all single and multiple mutations, but the degree of allosteric effect exerted on the endogenous ligand acetylcholine was affected at all mutants containing Y4267.39F. These findings will provide insights to consider when designing future mAChR ligands. SIGNIFICANCE STATEMENT: Structural studies demonstrated that three tyrosine residues between the orthosteric and allosteric sites of the M2 muscarinic acetylcholine receptor (mAChR) had different hydrogen bonding networks in the inactive and active conformations. The role of hydroxyl groups of the tyrosine residues on orthosteric and allosteric ligand pharmacology was unknown. We found that hydroxyl groups of the tyrosine residues differentially affected the molecular pharmacology of orthosteric and allosteric ligands. These results provide insights to consider when designing future mAChR ligands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Discovery Biology (V.P., G.T., A.C., D.M.T., C.V.), ARC Industrial Transformation Training Centre for Cryo-Electron Microscopy of Membrane Proteins (A.C., D.M.T.), Monash Institute of Pharmaceutical Sciences, Monas…
ORCID-Profile: Laura H Heitman, Arthur Christopoulos, Celine Valant
Förderung
- Wellcome Trust
Zitieren
APA
Pham, V., Habben Jansen, M. C. C., Thompson, G., Heitman, L. H., Christopoulos, A., Thal, D. M., & Valant, C. (2023). Role of Conserved Tyrosine Lid Residues in the Activation of the M2 Muscarinic Acetylcholine Receptor. Molecular Pharmacology. https://doi.org/10.1124/molpharm.122.000661
Vancouver
Pham V, Habben Jansen MCC, Thompson G, Heitman LH, Christopoulos A, Thal DM, et al. Role of Conserved Tyrosine Lid Residues in the Activation of the M2 Muscarinic Acetylcholine Receptor. Molecular Pharmacology. 2023. doi:10.1124/molpharm.122.000661
BibTeX
@article{Pham2023,
author = {Pham, Vi and Habben Jansen, Maria Clazina Cornelia and Thompson, Geoff and Heitman, Laura H and Christopoulos, Arthur and Thal, David M and Valant, Celine},
title = {Role of Conserved Tyrosine Lid Residues in the Activation of the M2 Muscarinic Acetylcholine Receptor},
journal = {Molecular Pharmacology},
year = {2023},
doi = {10.1124/molpharm.122.000661}
}
EUVIMED